Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474314 · ClinicalTrials.gov registry record · Phase 2
A Study of IMR-687 in Subjects With Sickle Cell Disease
A Phase 2 study, sponsored by Cardurion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT04474314: Clinical Trial Phase 2 study, sponsored by Cardurion Pharmaceuticals.
NCT04474314 is a Phase 2 study that was terminated before completion, run by Cardurion Pharmaceuticals. The registered enrollment target is 115 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04474314, a Phase 2 study, was terminated before completion, sponsored by Cardurion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
Primary Outcome
Annualized rate of VOCs. For each subject, the total number of VOCs on treatment were divided by the time on treatment divided by 52 weeks. The median was then summarized.
Interventions
- DRUG Placebo
- DRUG IMR-687
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2020-08-13 |
| Est. Completion | 2022-05-04 |
| Phase | Phase 2 |
Why NCT04474314 stopped before completion
NCT04474314 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04474314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04474314 about?
NCT04474314 is a clinical study titled "A Study of IMR-687 in Subjects With Sickle Cell Disease". A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
What is the current status of trial NCT04474314?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2020-08-13. Estimated completion is 2022-05-04.
What interventions are being tested in trial NCT04474314?
The interventions under investigation include: Placebo (DRUG), IMR-687 (DRUG).
Who is sponsoring clinical trial NCT04474314?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04474314's enrollment target sits among peer trials
115 626th of 2000 higher than 1,374 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI